Antares Pharma Financial Report from Smith On Stocks

Tuesday, March 9, 2021 · 2:27 pm

Tuesday, January 12, 2021 · 6:46 am

Tuesday, September 8, 2020 · 9:46 am

Wednesday, August 19, 2020 · 1:21 pm

Tuesday, May 19, 2020 · 9:16 am

Thursday, December 5, 2019 · 11:55 am

Friday, November 22, 2019 · 7:54 am

Wednesday, November 13, 2019 · 9:05 am

Wednesday, November 6, 2019 · 9:10 am

Wednesday, October 30, 2019 · 8:44 am

Monday, October 28, 2019 · 10:01 am

Wednesday, October 2, 2019 · 10:32 am

Tuesday, August 27, 2019 · 2:20 pm

Thursday, August 8, 2019 · 7:37 am

Tuesday, July 9, 2019 · 8:41 am

Wednesday, June 12, 2019 · 3:20 pm

Wednesday, June 5, 2019 · 9:26 am

Thursday, May 16, 2019 · 10:31 am

Monday, March 11, 2019 · 11:04 am

Thursday, February 28, 2019 · 11:28 am

Friday, November 30, 2018 · 2:59 pm

Wednesday, October 3, 2018 · 8:26 am

Tuesday, August 21, 2018 · 10:43 am

Wednesday, May 9, 2018 · 10:16 am

Monday, April 9, 2018 · 3:21 pm

Wednesday, March 28, 2018 · 7:47 am

Monday, March 5, 2018 · 12:13 pm

Friday, February 16, 2018 · 9:19 am

Tuesday, January 16, 2018 · 10:10 am

Monday, December 25, 2017 · 9:02 am

Thursday, November 9, 2017 · 9:07 am

Monday, October 23, 2017 · 10:06 am

Thursday, October 19, 2017 · 9:01 am

Thursday, August 17, 2017 · 10:26 am

Monday, April 17, 2017 · 11:08 am

Thursday, March 23, 2017 · 5:24 pm

Friday, February 3, 2017 · 10:15 am

Thursday, January 26, 2017 · 9:44 am

Tuesday, January 3, 2017 · 10:18 am

Wednesday, November 16, 2016 · 7:41 am

Monday, November 14, 2016 · 12:52 pm

Monday, September 26, 2016 · 11:15 am

Thursday, August 25, 2016 · 1:48 pm

Tuesday, August 23, 2016 · 11:04 am

Monday, June 27, 2016 · 11:25 am

Friday, June 3, 2016 · 3:55 pm

Wednesday, May 4, 2016 · 3:11 pm

Tuesday, May 3, 2016 · 4:50 pm

Friday, April 22, 2016 · 10:15 am

Monday, April 11, 2016 · 2:59 pm

Tuesday, March 1, 2016 · 10:49 am

Tuesday, December 15, 2015 · 11:41 am

Friday, November 6, 2015 · 10:53 am

Thursday, October 8, 2015 · 12:41 pm

Monday, August 10, 2015 · 10:51 am

Sunday, June 21, 2015 · 10:15 am

Thursday, April 23, 2015 · 11:27 am

Thursday, April 23, 2015 · 8:52 am

Sunday, November 23, 2014 · 9:14 am

Thursday, May 22, 2014 · 2:42 pm

Thursday, March 20, 2014 · 12:02 pm

Wednesday, January 22, 2014 · 3:48 pm

Tuesday, August 20, 2013 · 11:44 am

Tuesday, September 11, 2012 · 7:40 am

Saturday, April 28, 2012 · 7:01 am

Wednesday, March 28, 2012 · 4:49 pm

Wednesday, January 25, 2012 · 12:44 pm

Thursday, December 15, 2011 · 12:14 pm

Thursday, December 15, 2011 · 10:44 am

Thursday, December 15, 2011 · 10:37 am

Thursday, December 15, 2011 · 10:30 am

Thursday, December 15, 2011 · 10:23 am

There are 72 reports on file.

Reports on Antares Pharma

Recent Reports

Antares: The Future Looks Really, Really Bright (ATRS, Buy, $4.18)

Antares: Encouraging Revenue Guidance (ATRS, Buy, $4.00)

Antares: Xyosted Sales Projections for 2020 Through 2023 (ATRS, Buy, $2.62)

Why Bother with Antares? (ATRS, Buy, $2.86)

Antares (ATRS, Buy, $2.72) Effect of Covid-19 Appears Modest So Far On Company and Xyosted in Particular

Antares: Detailed Sales and Earnings Projections for 2020, 2021 and 2022 (ATRS, Buy, $4.86)

Antares Pharma: Highlights from Presentation at Jefferies Healthcare Conference: (ATRS, Buy, $4.79)

Antares Pharmaceuticals: Projecting Very Strong Growth in Xyosted Sales for 2020, 2021 and 2022 (ATRS, Buy, $3.89)

Antares Pharma: Quick Take on Implication of 3Q Results for Future Growth (ATRS, Buy, $3.70)

AMAG Pharmaceuticals: AdCom Votes 9 to 7 to Remove Makena from the Market, but I Don�t Think It Will Happen: �AMAG (AMAG, $9.80), Antares Pharma (ATRS, $3.40, Buy)

AMAG Pharmaceuticals (AMAG, $12.20); Antares (ATRS, Buy, $3.59) What Will FDA AdCom Recommend on Makena in the Aftermath of Failed Prolong Trial?

Antares: Impressive Xyosted Prescription Trends Continue (ATRS, Buy, $3.30)

Antares: Update on Sales Projections for Xyosted (ATRS, $3.30, Buy)

Antares: Highlights from 2Q, 2019 Conference Call (ATRS, $3.29, Buy)

Antares Pharma: The Xyosted Launch Continues to Look Good (ATRS, Buy, $3.37)

Antares Pharma: Detailed Sales and Earnings Model Through 2021 (ATRS, $2.85, Buy)

Antares Pharma: The Xyosted Launch Looks Like it will Meet or Beat Wall Street Expectations for 2019 (ATRS, Buy, $2.90)

Antares: Tracking Report on Xyosted Prescriptions (ATRS, Buy, $2.88)

Antares (ATRS, Buy, $3.51); AMAG Pharmaceuticals (AMAG, $11.73) First Thoughts about How the PROLONG Study Could Affect Makena Usage

Antares: Sales Growth Guidance for 2019 is Extremely Bullish (ATRS, $3.60, Buy)

Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59)

Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77)

Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy)

Antares: Recent Launch of Makena Subcu Auto Injector and Probable Launches of Xyosted and AB Rated Generic to EpiPen Could Make for an Outstanding Price Performance in 2018 (ATRS, Buy, $2.36)

Antares Pharma: Approval of Xyosted on or before September 29, 2018 Is Highly Probable (ATRS, Buy, $2.12)

Antares: FDA Comments from Type A Meeting Are a Best Case Outcome for Xyosted (ATRS, $2.13, Buy)

Antares: Things Are Looking Up (ATRS, Buy, $2.22)

Antares Pharma: Makena SC Approval is a Big Positve; There are more Approvals to Come (ATRS, Buy, $2.35)

Antares Pharma: Update on Xyosted (ATRS, Buy, $2.34)

Antares' Response to Complete Response Letter on Xyosted is in Line with My Expectations (ATRS, Buy, $2.05)

Antares Pharma: My Hypothesis on Issues that Resulted in the CRL for Xyosted and Potential Timing of Approval (ATRS. Buy, $1.63)

Antares: Approval of Xyosted is a Matter of When, Not If (ATRS, $2.12, Buy)

Antares Pharma: FDA Action to not Approve Xyosted on its October 20, 2017 PDUFA Date is Perplexing (ATRS, Buy, $2.23)

Antares Pharma: This Small, Emerging Biotechnology Company Is Poised for Explosive Growth Based on Five Major New Product Introductions by 2020 (ATRS, Buy, $3.02

Antares: AMAG Submits Supplemental New Drug Application to FDA for Makena� Auto-Injector for Subcutaneous Use: (Antares (ATRS, Buy, $2.86)

Antares: Pipeline is Bursting with Late Stage Products (ATRS, $2.77, Buy)

AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)

AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Antares: Teva Projects Launch of AB Rated Generic to EpiPen in Early 2018 (ATRS, Buy, $1.87)

Antares: Some Key Points from 3Q, 2016 Conference Call (ATRS, Buy, $1.84)

Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)

Antares; Are Mylan's Woes A Potential Positive for AB Rated Generic to EpiPen (ATRS, $1.37, Buy)

Antares: Comment on Strength in the Stock Price (ATRS, $1.29, Buy)

Antares Pharmaceuticals: Teva Launches AB Generic to Imitrex (ATRS, Buy, $1.06)

Antares Pharmaceuticals: Highlights on Makena from AMAG Pharmaceuticals Analyst Day (ATRS, $1.14, Buy)

Antares: Presentation Highlights from Deutsche Bank Conference (ATRS, Buy, $0.97)

Antares: AMAG Issues Guidance on Timing of Subcutaneous Makena (ATRS, Buy, $1/05)

Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92)

Antares: Makena Has the Potential to Make a Very Significant Contribution to EPS (ATRS, $0.85. Buy)

Antares: Disappointing News on AB Rated Version of EpiPen (ATRS, $0.95)

Antares: Undeterred by the Poor Stock Performance I Continue to Pound the Table (ATRS. Buy, $1.30)

Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)

Antares: The Stock Price Does Not Reflect the Fundamentals (ATRS, $1.60, Buy)

Quick Take on Antares Following 2Q, 2015 Conference Call (ATRS, Buy, $2.10)

Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)

Antares: Teva Offer to Buy Mylan Should Have No Effect on Launch of AB Rated Generic to EpiPen (ATRS, $2.76, Buy)

Antares: Detailed Sales and Earnings Projections for 2015 and 2016 (ATRS, Buy, $2.77, subscription required)

Antares: 2015 Could Be the Breakout Year for the Stock (ATRS, $2.24, Buy)

Antares: Although it is Still Early, I Think That Otrexup Launch is Going Very Well (ATRS, Buy, $2.93, Paid subscribers)

Antares (ATRS, Buy, $4.00) Why I Think That the Otrexup Launch Will Be A Success (Paid Subscribers Only)

San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)

Antares: An In-Depth Look at Otrexup and Re-iteration of My Buy Recommendation (ATRS: $4.45) (Paid Subscribers Only)

Antares' Pipeline is Bursting with New Products; Vibex MTX is the Star (ATRS)

Antares: Settlement of Litigation on EpiPen is a Positive (AIS, $3.08)

Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)

The Promise of the Antares Pipeline is the Basis of my Buy Recommendation (AIS, $2.40)

Antares Is Initated As A Buy Based On Broad, Promising Pipeline (AIS, $2.59)

Libi-Gel Phase III Trial Results Should Be Released Shortly (AIS, $2.73)

Collaboration with Teva on Self-Injected Drugs Is the Major Driver of the Investment Thesis (AIS, $2.68)

Approval of Anturol Is Significant Positive (AIS, $2.68)

Anturol's December 8th PDUFA Date Is Looming (AIS, $2.77)